Key Highlights

• Sonic reported Revenue of A$10,867m, up 13% with organic growth of 5%.

• Its summary said the midpoint implies growth of about A$57m, or about 3%, including close to A$30m of US restructuring benefits.

• Underlying EBITDA was A$1,933m, up 11%, and statutory EBITDA was A$1,882m, up 9%.

• Underlying net profit was A$621m, up 17%, and underlying Earnings Per Share were 125.6 cents, up 14%.

What does a diagnostics group do when its profit is growing mainly through acquisitions, while its organic momentum and some regulated prices are under pressure? Sonic Healthcare's (ASX:SHL) FY26 result, released on 20 August 2026 for the year to 30 June 2026, is a case study. Reported profit rose double digits, but the FY27 guidance, the US operating review and Swiss regulatory changes shape how investors read the next year.

The central development: acquired growth and a cautious outlook

Sonic reported revenue of A$10,867m, up 13% with organic growth of 5%. Underlying EBITDA was A$1,933m, up 11%, and statutory EBITDA was A$1,882m, up 9%. Underlying net profit was A$621m, up 17%, and underlying earnings per share were 125.6 cents, up 14%. The total Dividend was A$1.08 per share, up one cent. The company said it achieved its underlying EBITDA guidance.

Business and revenue drivers

Sonic is a global medical diagnostics company, with pathology (laboratory testing) as its largest activity, alongside radiology (imaging) and clinical services. Its operations span Australia, the United States, Germany, Switzerland, the United Kingdom and other European markets. Revenue depends on test volumes, mix (advanced diagnostics carry higher value), reimbursement rates set by governments and insurers, and labour and consumables costs. The release highlighted encouraging growth in advanced diagnostics.

Acquisition has been a core driver. The LADR Laboratory Group Acquisition in Germany was completed, with integration and synergies described as on schedule. Synergies from recent German and Swiss acquisitions were also realised, and the Brisbane hub laboratory was sold and leased back.

FY27 guidance and the swing factors

Its summary said the midpoint implies growth of about A$57m, or about 3%, including close to A$30m of US restructuring benefits. A separate summary indicated US initiatives were expected to add A$25m to A$30m to FY27 earnings; the figures are consistent in magnitude.

The offsets are material.

The US operating review

Sonic has started a comprehensive operating review of its US business. The US has been the weakest region for organic growth, in part because laboratory markets are competitive and payers push down prices. The review is the company's response and the restructuring benefits are the first measurable output. For investors the question is whether cost savings can offset sluggish volumes and whether a deeper strategic change, such as portfolio changes, follows.

Sector and competitive position

In Australia, Sonic competes mainly with Healius and Australian Clinical Labs in pathology and with other imaging providers. Overseas it competes with large operators such as Quest and Labcorp in the United States, and with regional laboratory groups in Europe. Its strength is scale, a diversified geography and a record of acquiring and integrating laboratories. Its weakness is exposure to government-set fee schedules in several markets and currency translation, because it reports in Australian dollars while earning heavily overseas.

Balance sheet and capital

Dividend maintenance with a one-cent increase suggests management's confidence in cash generation, though a dividend is not itself proof of balance-sheet capacity.

Risks and what to monitor

- Regulation and pricing: Swiss changes, German and UK contract terms, and US payer pressure all affect revenue per test.

- Integration: LADR synergies and UK contract integration must deliver as planned.

- US performance: weak organic growth and the outcome of the review.

- Currency: a more encouraging Australian dollar reduces reported earnings from overseas.

- Costs: wages and consumables Inflation in laboratories, which can erode Margin if fee schedules do not keep pace.

Key dates include the annual general meeting, which Sonic has typically held in November, and the half-year result in February 2027. The progress of the US review and LADR synergies will be the main operating signals.